The Best of Canadian Science and Technology
Content brought to you by:
The Cantech Letter Life Sciences section is brought to you by Relay Medical Corp. (CSNX:RELA). Relay is in the business of commercializing innovative technologies, protected by issued and pending patents, in the medical diagnostics and research field with an emphasis on In Vitro Diagnostics (IVD) and Point of Care Testing (POCT). Click on the logo for more info...
Expect the revenue ramp to keep climbing for StageZero Life Sciences (StageZero Life Sciences Stock Quote, Chart, News TSX:SZLS), according to Clarus … [Read more...] about Stage Zero Life Sciences could achieve a billion dollar market cap: Clarus
Clarus Securities analyst Noel Atkinson thinks there is huge upside in StageZero Life Sciences (StageZero Life Sciences Stock Quote, Chart, News … [Read more...] about StageZero Life Sciences has a massive upside, Clarus Securities says
Echelon Capital Markets analyst Douglas Loe is staying bullish on Canadian clinical-stage biopharmaceutical company IMV (IMV Stock Quote, Chart, News … [Read more...] about IMV still has a 50 per cent upside, Echelon Capital says
Drug developer Appili Therapeutics (Appili Therapeutics Stock Quote, Chart, News TSXV:APLI) has a pipeline ready to be unlocked, says Mackie Research … [Read more...] about Appili Therapeutics is undervalued, says Mackie Research
Specialty pharma company HLS Therapeutics (HLS Therapeutics Stock Quote, Chart, News TSX:HLS) just hit a couple of major milestones, says Stifel GMP … [Read more...] about HLS Therapeutics is undervalued, says Stifel
Biopharm company IMV (IMV Stock Quote, Chart, News TSX:IMV) is a high risk, high reward stock you should be looking at, says Industrial Alliance … [Read more...] about Industrial Alliance launches coverage of IMV with a “Buy” rating
Should you be buying IMV (IMV Stock Quote, Chart, News TSX:IMV)? The Halifax-based biopharm company now has the go-ahead to test its COVID-19 … [Read more...] about IMV gets new $10.50 price target from Echelon Capital
Medical tech company LexaGene (LexaGene Stock Quote, Chart, News TSXV:LXG) says the commercial launch of its flagship product, MiQLab, is just around … [Read more...] about LexaGene upgraded at Industrial Alliance Securities
Negative top-line results from its Phase 2 clinical study are cause for a rating change on Bellus Health (Bellus Health Stock Quote, Chart, News … [Read more...] about Bellus Health downgraded by Mackie Research
Liminal BioSciences (Liminal BioSciences Stock Quote, Chart, News TSX:LMNL) just had a major spike in its share price but Echelon Wealth analyst … [Read more...] about Don’t chase Liminal BioSciences, says Echelon Wealth
